Amphotericin B and micafungin duo-loaded nanoemulsion as a potential strategy against Candida auris biofilms.
Biofouling
; 40(9): 602-616, 2024 Oct.
Article
en En
| MEDLINE
| ID: mdl-39245976
ABSTRACT
Candida auris is a multidrug-resistant yeast that has seen a worrying increase during the COVID-19 pandemic. Give7/n this, new therapeutic options, such as controlled-release nanomaterials, may be promising in combating the infection. Therefore, this study aimed to develop amphotericin B (AmB) and micafungin (MICA)-loaded nanoemulsions (NEMA) and evaluated against biofilms of C. auris. Nanoemulsions (NEs) were characterized and determined minimum inhibitory concentration MIC90, checkerboard and anti-biofilm. NEMA presented a size of 53.7 and 81.4 nm for DLS and NTA, respectively, with good stability and spherical morphology. MICAmB incorporated efficiency was 88.4 and 99.3%, respectively. The release results show that AmB and MICA obtained a release of 100 and 63.4%, respectively. MICAmB and NEMA showed MIC90 values of 0.015 and 0.031 ug/mL, respectively and synergism. NEMA showed greater metabolic inhibition and morphological changes in mature biofilms. This drugs combination and co-encapsulation proved to be a promising therapy against C. auris biofilms.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Pruebas de Sensibilidad Microbiana
/
Anfotericina B
/
Biopelículas
/
Emulsiones
/
Micafungina
/
Candida auris
/
Antifúngicos
Límite:
Humans
Idioma:
En
Revista:
Biofouling
Asunto de la revista:
BIOLOGIA
Año:
2024
Tipo del documento:
Article
País de afiliación:
Brasil